---
audienceLevel: patient
cancerTypes:
- breast
- lung
- prostate
- pancreatic
- liver
citation: NCI, 2025
language: en
lastReviewed: '2025-12-30'
license: public_domain
reviewFrequency: quarterly
source: NCI
sourceType: 02_nci_core
status: active
tags:
- pdq
- treatment
title: Laetrile/Amygdalin (PDQ®) - NCI
url: https://www.cancer.gov/about-cancer/treatment/cam/hp/laetrile-pdq
version: v1
---

# Laetrile/Amygdalin (PDQ®) - NCI

# Laetrile/Amygdalin (PDQ®)–Health Professional Version

## Overview

[Go to Patient Version](/about-cancer/treatment/cam/patient/laetrile-pdq)

**NOTE: There is either no new research on this topic or the recent published research is weak and not appropriate for inclusion in the summary. Therefore, the information in this summary is no longer being updated and is provided for reference purposes only.**

This [cancer](/Common/PopUps/popDefinition.aspx?id=45333&version=healthprofessional&language=English&dictionary=Cancer.gov) information summary provides
an overview of the use of [laetrile](/Common/PopUps/popDefinition.aspx?id=444998&version=healthprofessional&language=English&dictionary=Cancer.gov) as a treatment for people with cancer. The summary
includes a history of laetrile research, a review of [laboratory studies](/Common/PopUps/popDefinition.aspx?id=44512&version=healthprofessional&language=English&dictionary=Cancer.gov), the
results of [clinical trials](/Common/PopUps/popDefinition.aspx?id=45961&version=healthprofessional&language=English&dictionary=Cancer.gov), and possible [side effects](/Common/PopUps/popDefinition.aspx?id=46580&version=healthprofessional&language=English&dictionary=Cancer.gov) of laetrile use.

This summary contains the following key information:

- Laetrile is another name for the natural product [amygdalin](/Common/PopUps/popDefinition.aspx?id=454511&version=healthprofessional&language=English&dictionary=Cancer.gov), which is a [chemical](/Common/PopUps/popDefinition.aspx?id=643008&version=healthprofessional&language=English&dictionary=Cancer.gov) constituent found in
the pits of many fruits and in numerous plants.
- [Hydrogen cyanide](/Common/PopUps/popDefinition.aspx?id=686192&version=healthprofessional&language=English&dictionary=Cancer.gov) is thought to be the main anticancer [compound](/Common/PopUps/popDefinition.aspx?id=422394&version=healthprofessional&language=English&dictionary=Cancer.gov) formed from laetrile via *in situ* release.
- Laetrile was first used as a cancer treatment in Russia in 1845, and in
the United States in the 1920s.
- Laetrile has shown little anticancer activity in [animal studies](/Common/PopUps/popDefinition.aspx?id=454774&version=healthprofessional&language=English&dictionary=Cancer.gov) and no
anticancer activity in human clinical
trials.
- The side effects associated with laetrile [toxicity](/Common/PopUps/popDefinition.aspx?id=445093&version=healthprofessional&language=English&dictionary=Cancer.gov) mirror the symptoms of cyanide poisoning, including [liver](/Common/PopUps/popDefinition.aspx?id=46312&version=healthprofessional&language=English&dictionary=Cancer.gov) damage, difficulty walking (caused by damaged [nerves](/Common/PopUps/popDefinition.aspx?id=373935&version=healthprofessional&language=English&dictionary=Cancer.gov)), [fever](/Common/PopUps/popDefinition.aspx?id=450108&version=healthprofessional&language=English&dictionary=Cancer.gov), [coma](/Common/PopUps/popDefinition.aspx?id=476351&version=healthprofessional&language=English&dictionary=Cancer.gov), and death.
- Laetrile is not approved for use in the United States.
- Inappropriate advertisement of laetrile as a cancer treatment resulted in a [U.S. Food and Drug Administration](/Common/PopUps/popDefinition.aspx?id=454785&version=healthprofessional&language=English&dictionary=Cancer.gov) investigation that culminated in charges and conviction of one distributor.

Many of the medical and scientific terms used in this summary are hypertext linked (at first use in each section) to the [NCI Dictionary of Cancer Terms](https://www.cancer.gov/publications/dictionaries/cancer-terms/ "https://www.cancer.gov/publications/dictionaries/cancer-terms/"), which is oriented toward nonexperts. When a linked term is clicked, a definition will appear in a separate window.

Reference citations in some [PDQ](/Common/PopUps/popDefinition.aspx?id=44271&version=healthprofessional&language=English&dictionary=Cancer.gov) cancer information summaries may include links to external websites that are operated by individuals or organizations for the purpose of marketing or advocating the use of specific treatments or products. These reference citations are included for informational purposes only. Their inclusion should not be viewed as an endorsement of the content of the websites, or of any treatment or product, by the PDQ Integrative, Alternative, and Complementary Therapies Editorial Board or the [National Cancer Institute](/Common/PopUps/popDefinition.aspx?id=44266&version=healthprofessional&language=English&dictionary=Cancer.gov).

## General Information

The term *[laetrile](/Common/PopUps/popDefinition.aspx?id=444998&version=healthprofessional&language=English&dictionary=Cancer.gov)* is derived from the terms laevorotatory and mandelonitrile and is used
to describe a purified form of the chemical [amygdalin](/Common/PopUps/popDefinition.aspx?id=454511&version=healthprofessional&language=English&dictionary=Cancer.gov), a
[cyanogenic glucoside](/Common/PopUps/popDefinition.aspx?id=44018&version=healthprofessional&language=English&dictionary=Cancer.gov) found in the pits of
many fruits and raw nuts and in other plants, such as lima beans, clover, and
sorghum.[[1](#cit/section_2.1)-[6](#cit/section_2.6)] In body [fluids](/Common/PopUps/popDefinition.aspx?id=44669&version=healthprofessional&language=English&dictionary=Cancer.gov) and at [physiological](/Common/PopUps/popDefinition.aspx?id=45837&version=healthprofessional&language=English&dictionary=Cancer.gov) [pH](/Common/PopUps/popDefinition.aspx?id=747897&version=healthprofessional&language=English&dictionary=Cancer.gov), [hydrogen cyanide](/Common/PopUps/popDefinition.aspx?id=686192&version=healthprofessional&language=English&dictionary=Cancer.gov) dissolves to form the cyanide anion. The term *vitamin B-17* was given to laetrile by E.T. Krebs Jr, but it is not an approved designation by the Committee on Nomenclature of the American Institute of Nutrition Vitamins. In the 1970s, laetrile gained popularity as an
anticancer agent. By 1978, more than 70,000 individuals in the United States
were reported to have been treated with it.[[2](#cit/section_2.2),[7](#cit/section_2.7),[8](#cit/section_2.8)]

Laetrile has
been used for [cancer](/Common/PopUps/popDefinition.aspx?id=45333&version=healthprofessional&language=English&dictionary=Cancer.gov) treatment both as a single agent and in combination with
a [metabolic therapy](/Common/PopUps/popDefinition.aspx?id=44057&version=healthprofessional&language=English&dictionary=Cancer.gov) program
that consists of a specialized diet, high-dose [vitamin](/Common/PopUps/popDefinition.aspx?id=44744&version=healthprofessional&language=English&dictionary=Cancer.gov) supplements, and [pancreatic enzymes](/Common/PopUps/popDefinition.aspx?id=46704&version=healthprofessional&language=English&dictionary=Cancer.gov).[[9](#cit/section_2.9),[10](#cit/section_2.10)]

In the United States, researchers must file an [Investigational New Drug](/Common/PopUps/popDefinition.aspx?id=762975&version=healthprofessional&language=English&dictionary=Cancer.gov)
(IND) application with the [U.S. Food and Drug Administration](/Common/PopUps/popDefinition.aspx?id=454785&version=healthprofessional&language=English&dictionary=Cancer.gov) (FDA) to conduct
drug research in human subjects. In 1970, an IND
application to study laetrile was filed by the McNaughton Foundation (San Ysidro,
California). This request was initially approved but later rejected because
[preclinical](/Common/PopUps/popDefinition.aspx?id=44517&version=healthprofessional&language=English&dictionary=Cancer.gov) evidence in animals showed that laetrile was not likely to be
effective as an anticancer agent,[[3](#cit/section_2.3),[11](#cit/section_2.11),[12](#cit/section_2.12)] and because there were
questions about how the proposed study was to be conducted.[[13](#cit/section_2.13)]
Laetrile supporters viewed this reversal as an attempt by the U.S. government
to block access to new and promising cancer [therapies](/Common/PopUps/popDefinition.aspx?id=44737&version=healthprofessional&language=English&dictionary=Cancer.gov), and pressure mounted to
make laetrile available to the public. Court cases in Oklahoma,
Massachusetts, New Jersey, and California challenged the FDA’s role in
determining which drugs should be available to cancer patients. Consequently,
laetrile was legalized in more than 20 states during the 1970s. In 1980, the
U.S. Supreme Court acted to uphold a federal ban on interstate shipment of laetrile.[[2](#cit/section_2.2),[14](#cit/section_2.14)] As a result, the
use of laetrile has greatly diminished, but
the compound continues to be manufactured and administered as an anticancer therapy,
primarily in Mexico, and in some clinics in the United States.

Although the names laetrile, Laetrile, vitamin B-17, and amygdalin are often used
interchangeably, they are not the same product. The chemical composition of
U.S.-patented Laetrile (mandelonitrile-beta-glucuronide), a semisynthetic
[derivative](/Common/PopUps/popDefinition.aspx?id=44022&version=healthprofessional&language=English&dictionary=Cancer.gov) of amygdalin, is different
from the laetrile/amygdalin produced in Mexico (mandelonitrile
beta-D-gentiobioside), which is made from crushed apricot pits.[[15](#cit/section_2.15),[16](#cit/section_2.16)] Mandelonitrile, which contains a cyanide group, is a structural component of
both products.[[15](#cit/section_2.15)] It has been proposed that released (hydrogen) cyanide is the
active cancer-killing ingredient in laetrile, but two other breakdown products
of amygdalin—prunasin (which is similar in structure to Laetrile) and
[benzaldehyde](/Common/PopUps/popDefinition.aspx?id=44000&version=healthprofessional&language=English&dictionary=Cancer.gov)—may also be cancer
[cell](/Common/PopUps/popDefinition.aspx?id=46476&version=healthprofessional&language=English&dictionary=Cancer.gov) inhibitors.[[17](#cit/section_2.17)-[20](#cit/section_2.20)] The studies discussed in this summary used
either Mexican laetrile/amygdalin or the patented form. In most instances,
the generic term *laetrile* will be used in this summary; however, a distinction will be
made between the products when necessary.

Laetrile can be administered [orally](/Common/PopUps/popDefinition.aspx?id=44068&version=healthprofessional&language=English&dictionary=Cancer.gov) as
a pill, or it can be given by [injection](/Common/PopUps/popDefinition.aspx?id=44678&version=healthprofessional&language=English&dictionary=Cancer.gov) ([intravenous](/Common/PopUps/popDefinition.aspx?id=46682&version=healthprofessional&language=English&dictionary=Cancer.gov) or [intramuscular](/Common/PopUps/popDefinition.aspx?id=44048&version=healthprofessional&language=English&dictionary=Cancer.gov)). It is commonly given
intravenously for a period of time followed by oral [maintenance therapy](/Common/PopUps/popDefinition.aspx?id=45768&version=healthprofessional&language=English&dictionary=Cancer.gov). The
incidence of cyanide poisoning is much higher when laetrile is taken orally
[[21](#cit/section_2.21)-[23](#cit/section_2.23)] because [intestinal](/Common/PopUps/popDefinition.aspx?id=44046&version=healthprofessional&language=English&dictionary=Cancer.gov) [bacteria](/Common/PopUps/popDefinition.aspx?id=44123&version=healthprofessional&language=English&dictionary=Cancer.gov) and some commonly
eaten plants contain [enzymes](/Common/PopUps/popDefinition.aspx?id=46081&version=healthprofessional&language=English&dictionary=Cancer.gov)
(beta-glucosidases) that activate the release of cyanide after laetrile has
been [ingested](/Common/PopUps/popDefinition.aspx?id=44100&version=healthprofessional&language=English&dictionary=Cancer.gov).[[17](#cit/section_2.17),[22](#cit/section_2.22)] Relatively little breakdown occurs to yield the (hydrogen) cyanide
when laetrile is injected.[[7](#cit/section_2.7),[22](#cit/section_2.22)] Administration schedules
and the length of treatment in [animal models](/Common/PopUps/popDefinition.aspx?id=43996&version=healthprofessional&language=English&dictionary=Cancer.gov) and humans vary
widely.

###### References

1. Howard-Ruben J, Miller NJ: Unproven methods of cancer management. Part II: Current trends and implications for patient care. Oncol Nurs Forum 11 (1): 67-73, 1984 Jan-Feb. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=6318190&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=6318190&dopt=Abstract")
2. Curt GA: Unsound methods of cancer treatment. Princ Pract Oncol Updates 4 (12): 1-10, 1990.
3. Dorr RT, Paxinos J: The current status of laetrile. Ann Intern Med 89 (3): 389-97, 1978. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=356691&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=356691&dopt=Abstract")
4. Calabrese EJ: Possible adverse side effects from treatment with laetrile. Med Hypotheses 5 (9): 1045-9, 1979. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=522706&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=522706&dopt=Abstract")
5. The laetrile controversy. In: Moss RW: The Cancer Industry: The Classic Expose on the Cancer Establishment. First Equinox Press, 1996, pp 131-52.
6. Laetrile at Sloan-Kettering: a case study. In: Moss RW: The Cancer Industry: The Classic Expose on the Cancer Establishment. First Equinox Press, 1996, pp 153-86.
7. Lerner IJ: Laetrile: a lesson in cancer quackery. CA Cancer J Clin 31 (2): 91-5, 1981 Mar-Apr. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=6781723&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=6781723&dopt=Abstract")
8. Ellison NM, Byar DP, Newell GR: Special report on Laetrile: the NCI Laetrile Review. Results of the National Cancer Institute's retrospective Laetrile analysis. N Engl J Med 299 (10): 549-52, 1978. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=683212&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=683212&dopt=Abstract")
9. Moertel CG, Fleming TR, Rubin J, et al.: A clinical trial of amygdalin (Laetrile) in the treatment of human cancer. N Engl J Med 306 (4): 201-6, 1982. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7033783&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7033783&dopt=Abstract")
10. Ross WE: Unconventional cancer therapy. Compr Ther 11 (9): 37-43, 1985. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=4042595&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=4042595&dopt=Abstract")
11. Lewis JP: Laetrile. West J Med 127 (1): 55-62, 1977. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=327697&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=327697&dopt=Abstract")
12. Unproven methods of cancer management. Laetrile. CA Cancer J Clin 22 (4): 245-50, 1972 Jul-Aug. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=4625050&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=4625050&dopt=Abstract")
13. Rosen GM, Shorr RI: Laetrile: end play around the FDA. A review of legal developments. Ann Intern Med 90 (3): 418-23, 1979. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=371476&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=371476&dopt=Abstract")
14. Curran WJ: Law-medicine notes. Laetrile for the terminally ill: Supreme Court stops the nonsense. N Engl J Med 302 (11): 619-21, 1980. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7351911&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7351911&dopt=Abstract")
15. Fenselau C, Pallante S, Batzinger RP, et al.: Mandelonitrile beta-glucuronide: synthesis and characterization. Science 198 (4317): 625-7, 1977. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=335509&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=335509&dopt=Abstract")
16. Chandler RF, Anderson LA, Phillipson JD: Laetrile in perspective. Can Pharm J 117 (11): 517-20, 1984.
17. Newmark J, Brady RO, Grimley PM, et al.: Amygdalin (Laetrile) and prunasin beta-glucosidases: distribution in germ-free rat and in human tumor tissue. Proc Natl Acad Sci U S A 78 (10): 6513-6, 1981. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=6796962&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=6796962&dopt=Abstract")
18. Rauws AG, Olling M, Timmerman A: The pharmacokinetics of prunasin, a metabolite of amygdalin. J Toxicol Clin Toxicol 19 (8): 851-6, 1982. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7182513&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7182513&dopt=Abstract")
19. Kochi M, Takeuchi S, Mizutani T, et al.: Antitumor activity of benzaldehyde. Cancer Treat Rep 64 (1): 21-3, 1980. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=6929727&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=6929727&dopt=Abstract")
20. Kochi M, Isono N, Niwayama M, et al.: Antitumor activity of a benzaldehyde derivative. Cancer Treat Rep 69 (5): 533-7, 1985. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=4005876&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=4005876&dopt=Abstract")
21. Gostomski FE: The effects of amygdalin on the Krebs-2 carcinoma and adult and fetal DUB(ICR) mice. [Abstract] Diss Abstr Int B 39 (5): 2075-B, 1978.
22. Herbert V: Laetrile: the cult of cyanide. Promoting poison for profit. Am J Clin Nutr 32 (5): 1121-58, 1979. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=219680&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=219680&dopt=Abstract")
23. Viehoever A, Mack H: Bio-chemistry of amygdalin (bitter, cyanogenetic principle from bitter almonds). Am J Pharm 107 (Oct): 397-450, 1935.

## History

[Amygdalin](/Common/PopUps/popDefinition.aspx?id=454511&version=healthprofessional&language=English&dictionary=Cancer.gov) was first isolated in 1830 by two French chemists.[[1](#cit/section_3.1),[2](#cit/section_3.2)] It was used as an anticancer agent in Russia as early as 1845, and
positive results were reported for the first patient treated.[[3](#cit/section_3.3),[4](#cit/section_3.4)] The first recorded use of amygdalin in the United States as a treatment for [cancer](/Common/PopUps/popDefinition.aspx?id=45333&version=healthprofessional&language=English&dictionary=Cancer.gov) occurred in
the early 1920s.[[5](#cit/section_3.5)] At that time, amygdalin was taken in pill
form; however, the formulation was judged too [toxic](/Common/PopUps/popDefinition.aspx?id=43986&version=healthprofessional&language=English&dictionary=Cancer.gov), and the work was
abandoned. In the 1950s, a purportedly [nontoxic](/Common/PopUps/popDefinition.aspx?id=44509&version=healthprofessional&language=English&dictionary=Cancer.gov) [intravenous](/Common/PopUps/popDefinition.aspx?id=46682&version=healthprofessional&language=English&dictionary=Cancer.gov) form of amygdalin
was patented as [Laetrile](/Common/PopUps/popDefinition.aspx?id=444998&version=healthprofessional&language=English&dictionary=Cancer.gov).[[1](#cit/section_3.1),[6](#cit/section_3.6),[7](#cit/section_3.7)]

Laetrile has been tested on [cultured animal cells](/Common/PopUps/popDefinition.aspx?id=44017&version=healthprofessional&language=English&dictionary=Cancer.gov), in whole animals, in [xenograft](/Common/PopUps/popDefinition.aspx?id=44095&version=healthprofessional&language=English&dictionary=Cancer.gov) models, and in humans to determine whether
it has specific anticancer properties. As noted in the [General Information](/about-cancer/treatment/cam/hp/laetrile-pdq#_5) section, [hydrogen cyanide](/Common/PopUps/popDefinition.aspx?id=686192&version=healthprofessional&language=English&dictionary=Cancer.gov) is believed to be the main cancer-killing ingredient in
laetrile.[[8](#cit/section_3.8),[9](#cit/section_3.9)] When amygdalin interacts with the [enzyme](/Common/PopUps/popDefinition.aspx?id=46081&version=healthprofessional&language=English&dictionary=Cancer.gov) beta-glucosidase
or undergoes [hydrolysis](/Common/PopUps/popDefinition.aspx?id=44037&version=healthprofessional&language=English&dictionary=Cancer.gov) in the absence of enzymes, hydrogen cyanide,
[benzaldehyde](/Common/PopUps/popDefinition.aspx?id=44000&version=healthprofessional&language=English&dictionary=Cancer.gov), and [glucose](/Common/PopUps/popDefinition.aspx?id=44033&version=healthprofessional&language=English&dictionary=Cancer.gov) are
produced.[[1](#cit/section_3.1),[7](#cit/section_3.7),[8](#cit/section_3.8),[10](#cit/section_3.10),[11](#cit/section_3.11)] Hydrogen cyanide can also be produced from
prunasin, which is a less-than-complete breakdown product of
amygdalin.[[1](#cit/section_3.1),[8](#cit/section_3.8)]

Proponents of laetrile have proposed four different theories to explain its purported anticancer activity. The first of these incorporates elements of the
trophoblastic theory of cancer, a theory that is not widely accepted as an
explanation for cancer formation. According to the trophoblastic theory, all
cancers arise from primordial [germ cells](/Common/PopUps/popDefinition.aspx?id=46382&version=healthprofessional&language=English&dictionary=Cancer.gov), some of which become
dispersed throughout the body during
[embryonic](/Common/PopUps/popDefinition.aspx?id=44250&version=healthprofessional&language=English&dictionary=Cancer.gov) development and, therefore, are not confined to the [testes](/Common/PopUps/popDefinition.aspx?id=367406&version=healthprofessional&language=English&dictionary=Cancer.gov) or
[ovaries](/Common/PopUps/popDefinition.aspx?id=46687&version=healthprofessional&language=English&dictionary=Cancer.gov).[[12](#cit/section_3.12)-[17](#cit/section_3.17)] The rationale
for laetrile use is the suggestion that [malignant](/Common/PopUps/popDefinition.aspx?id=45772&version=healthprofessional&language=English&dictionary=Cancer.gov) [cells](/Common/PopUps/popDefinition.aspx?id=46476&version=healthprofessional&language=English&dictionary=Cancer.gov) have higher than
normal levels of an enzyme called beta-glucuronidase (which is different from
the enzyme beta-glucosidase) and that they are deficient in
another enzyme called rhodanese (thiosulfate sulfurtransferase). Another suggestion is that laetrile is modified in the [liver](/Common/PopUps/popDefinition.aspx?id=46312&version=healthprofessional&language=English&dictionary=Cancer.gov), and that
beta-glucuronidase breaks down the modified compound, ultimately producing
cyanide. Rhodanese can convert cyanide into the relatively harmless compound
thiocyanate. Thus, it has been proposed that cancer cells are more
susceptible to the toxic effects of laetrile than normal cells because of an
imbalance in these two enzymes.[[10](#cit/section_3.10),[13](#cit/section_3.13),[18](#cit/section_3.18)-[20](#cit/section_3.20)] Some experimental evidence does support the idea that normal
[tissues](/Common/PopUps/popDefinition.aspx?id=46683&version=healthprofessional&language=English&dictionary=Cancer.gov) and malignant tissues differ substantially in their concentrations of
beta-glucuronidase [[21](#cit/section_3.21)] and rhodanese.[[22](#cit/section_3.22),[23](#cit/section_3.23)]

The second theory states that cancer cells contain more beta-glucosidase
activity than normal cells and, as in the first theory, that they are
deficient in rhodanese.[[1](#cit/section_3.1),[5](#cit/section_3.5),[13](#cit/section_3.13),[15](#cit/section_3.15),[18](#cit/section_3.18),[24](#cit/section_3.24),[25](#cit/section_3.25)] Again, elevated beta-glucosidase activity in the interstitial regions of some [malignancies](/Common/PopUps/popDefinition.aspx?id=45771&version=healthprofessional&language=English&dictionary=Cancer.gov) has been experimentally demonstrated.[[26](#cit/section_3.26),[27](#cit/section_3.27)]

The third theory states that cancer is the result of a [metabolic disorder](/Common/PopUps/popDefinition.aspx?id=44055&version=healthprofessional&language=English&dictionary=Cancer.gov) caused by a
[vitamin](/Common/PopUps/popDefinition.aspx?id=44744&version=healthprofessional&language=English&dictionary=Cancer.gov) [deficiency](/Common/PopUps/popDefinition.aspx?id=321364&version=healthprofessional&language=English&dictionary=Cancer.gov). It states further that laetrile, or *amygdalin/vitamin B-17*, is
the missing vitamin needed by the body to restore health.[[18](#cit/section_3.18),[28](#cit/section_3.28)-[30](#cit/section_3.30)] Experimental evidence indicates that the level of intake of
individual vitamins and/or the vitamin status of an [organism](/Common/PopUps/popDefinition.aspx?id=46250&version=healthprofessional&language=English&dictionary=Cancer.gov) can influence the development of
cancer, but there is no evidence that laetrile is needed for normal [metabolism](/Common/PopUps/popDefinition.aspx?id=46173&version=healthprofessional&language=English&dictionary=Cancer.gov) or that it can function as a
vitamin in animals or humans.[[31](#cit/section_3.31),[32](#cit/section_3.32)]

The fourth theory suggests that the cyanide released by laetrile has a
toxic effect beyond its interference with oxygen utilization by cells.
According to this theory, cyanide increases the acid content of [tumors](/Common/PopUps/popDefinition.aspx?id=46634&version=healthprofessional&language=English&dictionary=Cancer.gov) and
leads to the destruction of [lysosomes](/Common/PopUps/popDefinition.aspx?id=44053&version=healthprofessional&language=English&dictionary=Cancer.gov). The injured
lysosomes release their contents, thereby killing the cancer cells and
arresting tumor growth.[[15](#cit/section_3.15)] According to this theory, another
consequence of lysosome disruption is stimulation of the [immune system](/Common/PopUps/popDefinition.aspx?id=46356&version=healthprofessional&language=English&dictionary=Cancer.gov).

###### References

1. Dorr RT, Paxinos J: The current status of laetrile. Ann Intern Med 89 (3): 389-97, 1978. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=356691&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=356691&dopt=Abstract")
2. Viehoever A, Mack H: Bio-chemistry of amygdalin (bitter, cyanogenetic principle from bitter almonds). Am J Pharm 107 (Oct): 397-450, 1935.
3. The laetrile controversy. In: Moss RW: The Cancer Industry: The Classic Expose on the Cancer Establishment. First Equinox Press, 1996, pp 131-52.
4. Laetrile at Sloan-Kettering: a case study. In: Moss RW: The Cancer Industry: The Classic Expose on the Cancer Establishment. First Equinox Press, 1996, pp 153-86.
5. Curt GA: Unsound methods of cancer treatment. Princ Pract Oncol Updates 4 (12): 1-10, 1990.
6. Fenselau C, Pallante S, Batzinger RP, et al.: Mandelonitrile beta-glucuronide: synthesis and characterization. Science 198 (4317): 625-7, 1977. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=335509&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=335509&dopt=Abstract")
7. Chandler RF, Anderson LA, Phillipson JD: Laetrile in perspective. Can Pharm J 117 (11): 517-20, 1984.
8. Newmark J, Brady RO, Grimley PM, et al.: Amygdalin (Laetrile) and prunasin beta-glucosidases: distribution in germ-free rat and in human tumor tissue. Proc Natl Acad Sci U S A 78 (10): 6513-6, 1981. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=6796962&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=6796962&dopt=Abstract")
9. Rauws AG, Olling M, Timmerman A: The pharmacokinetics of prunasin, a metabolite of amygdalin. J Toxicol Clin Toxicol 19 (8): 851-6, 1982. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7182513&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7182513&dopt=Abstract")
10. Ross WE: Unconventional cancer therapy. Compr Ther 11 (9): 37-43, 1985. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=4042595&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=4042595&dopt=Abstract")
11. Ames MM, Moyer TP, Kovach JS, et al.: Pharmacology of amygdalin (laetrile) in cancer patients. Cancer Chemother Pharmacol 6 (1): 51-7, 1981. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7273266&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7273266&dopt=Abstract")
12. Krebs ET Jr, Krebs ET Sr, Beard HH: The unitarian or trophoblastic thesis of cancer. Med Rec 163 (7): 149-74, 1950.
13. Ellison NM: Unproven methods of cancer therapy. Drug Ther (NY) 10(July): 73-82, 1980.
14. Navarro MD: The Philippine experience in the early detection and chemotherapy of cancer. St Tomas J Med 25 (3): 125-33, 1970.
15. Greenberg DM: The case against laetrile: the fraudulent cancer remedy. Cancer 45 (4): 799-807, 1980. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=6986971&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=6986971&dopt=Abstract")
16. Levi L, French WN, Bickis IJ, et al.: Laetrile: a study of its physicochemical and biochemical properties. Can Med Assoc J 92 (20): 1057-61, 1965.
17. Treatment of cancer with laetriles; a report by the Cancer Commission of the California Medical Association. Calif Med 78 (4): 320-6, 1953. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=13042670&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=13042670&dopt=Abstract")
18. Unproven methods of cancer management. Laetrile. CA Cancer J Clin 22 (4): 245-50, 1972 Jul-Aug. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=4625050&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=4625050&dopt=Abstract")
19. Navarro MD: Five years experience with laetrile therapy in advanced cancer. Acta Unio Int Contr Cancrum 15(suppl 1): 209-21, 1959.
20. Morrone JA: Chemotherapy of inoperable cancer: preliminary report of 10 cases treated with laetrile. Exp Med Surg 20: 299-308, 1962.
21. Chen X, Wu B, Wang PG: Glucuronides in anti-cancer therapy. Curr Med Chem Anticancer Agents 3 (2): 139-50, 2003. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12678908&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12678908&dopt=Abstract")
22. GAL EM, FUNG FH, GREENBERG DM: Studies on the biological action of malononitriles. II. Distribution of rhodanese (transulfurase) in the tissues of normal and tumor-bearing animals and the effect of malononitriles thereon. Cancer Res 12 (8): 574-9, 1952. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=14945048&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=14945048&dopt=Abstract")
23. Sabelli R, Iorio E, De Martino A, et al.: Rhodanese-thioredoxin system and allyl sulfur compounds. FEBS J 275 (15): 3884-99, 2008. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=18616471&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=18616471&dopt=Abstract")
24. Herbert V: Laetrile: the cult of cyanide. Promoting poison for profit. Am J Clin Nutr 32 (5): 1121-58, 1979. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=219680&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=219680&dopt=Abstract")
25. Scott PJ: Laetrile and cancer quackery problems. Cancer Forum 5 (2): 93-97, 1981.
26. Cheng H, Cao X, Xian M, et al.: Synthesis and enzyme-specific activation of carbohydrate-geldanamycin conjugates with potent anticancer activity. J Med Chem 48 (2): 645-52, 2005. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15658879&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15658879&dopt=Abstract")
27. Bernacki RJ, Niedbala MJ, Korytnyk W: Glycosidases in cancer and invasion. Cancer Metastasis Rev 4 (1): 81-101, 1985. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=3888385&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=3888385&dopt=Abstract")
28. Lerner IJ: Laetrile: a lesson in cancer quackery. CA Cancer J Clin 31 (2): 91-5, 1981 Mar-Apr. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=6781723&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=6781723&dopt=Abstract")
29. Lerner IJ: The whys of cancer quackery. Cancer 53 (3 Suppl): 815-9, 1984. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=6362828&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=6362828&dopt=Abstract")
30. Shils ME, Hermann MG: Unproved dietary claims in the treatment of patients with cancer. Bull N Y Acad Med 58 (3): 323-40, 1982. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7052177&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7052177&dopt=Abstract")
31. Young VR, Newberne PM: Vitamins and cancer prevention: issues and dilemmas. Cancer 47 (5 Suppl): 1226-40, 1981. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7237379&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7237379&dopt=Abstract")
32. Jukes TH: Is laetrile a vitamin? Nutr Today 12 (5): 12-17, 1977.

## Laboratory/Animal/Preclinical Studies

[Preclinical](/Common/PopUps/popDefinition.aspx?id=44517&version=healthprofessional&language=English&dictionary=Cancer.gov) investigations of the potential anticancer activity of [laetrile](/Common/PopUps/popDefinition.aspx?id=444998&version=healthprofessional&language=English&dictionary=Cancer.gov) have used numerous
[cultured cell lines](/Common/PopUps/popDefinition.aspx?id=44016&version=healthprofessional&language=English&dictionary=Cancer.gov) and
[tumor models](/Common/PopUps/popDefinition.aspx?id=44091&version=healthprofessional&language=English&dictionary=Cancer.gov), and they explored the
following issues:

- Whether laetrile, given alone or in combination with
other substances, exhibits anticancer activity of any kind.
- The [toxic](/Common/PopUps/popDefinition.aspx?id=43986&version=healthprofessional&language=English&dictionary=Cancer.gov)
effects associated with laetrile treatment.
- The location of laetrile
breakdown in the body, and how this breakdown occurs.
- The route(s) of
[excretion](/Common/PopUps/popDefinition.aspx?id=476338&version=healthprofessional&language=English&dictionary=Cancer.gov) for laetrile and its broken-down products.

[Animal studies](/Common/PopUps/popDefinition.aspx?id=454774&version=healthprofessional&language=English&dictionary=Cancer.gov) of laetrile have used rodents,[[1](#cit/section_4.1)-[10](#cit/section_4.10)] dogs,[[11](#cit/section_4.11)-[13](#cit/section_4.13)] rabbits,[[13](#cit/section_4.13)] and a cat.[[11](#cit/section_4.11)] Early work led to the
[hypothesis](/Common/PopUps/popDefinition.aspx?id=44209&version=healthprofessional&language=English&dictionary=Cancer.gov) that [enzymes](/Common/PopUps/popDefinition.aspx?id=46081&version=healthprofessional&language=English&dictionary=Cancer.gov) were necessary to release [hydrogen cyanide](/Common/PopUps/popDefinition.aspx?id=686192&version=healthprofessional&language=English&dictionary=Cancer.gov) from [amygdalin](/Common/PopUps/popDefinition.aspx?id=454511&version=healthprofessional&language=English&dictionary=Cancer.gov).
When high levels of these enzymes were present, [symptoms](/Common/PopUps/popDefinition.aspx?id=45022&version=healthprofessional&language=English&dictionary=Cancer.gov) of cyanide poisoning
were more pronounced.[[1](#cit/section_4.1),[13](#cit/section_4.13)]

In two studies sponsored by the
[National Cancer Institute](/Common/PopUps/popDefinition.aspx?id=44266&version=healthprofessional&language=English&dictionary=Cancer.gov) and published in 1975, various rodent cancers
([osteogenic sarcoma](/Common/PopUps/popDefinition.aspx?id=44069&version=healthprofessional&language=English&dictionary=Cancer.gov),
[melanoma](/Common/PopUps/popDefinition.aspx?id=45135&version=healthprofessional&language=English&dictionary=Cancer.gov), [carcinosarcoma](/Common/PopUps/popDefinition.aspx?id=44003&version=healthprofessional&language=English&dictionary=Cancer.gov), [lung](/Common/PopUps/popDefinition.aspx?id=270740&version=healthprofessional&language=English&dictionary=Cancer.gov)
[carcinoma](/Common/PopUps/popDefinition.aspx?id=45963&version=healthprofessional&language=English&dictionary=Cancer.gov), and [leukemia](/Common/PopUps/popDefinition.aspx?id=45343&version=healthprofessional&language=English&dictionary=Cancer.gov)) were [transplanted](/Common/PopUps/popDefinition.aspx?id=46631&version=healthprofessional&language=English&dictionary=Cancer.gov) into rats and mice.[[2](#cit/section_4.2),[3](#cit/section_4.3)] In both
studies, the animals were treated with [intraperitoneal](/Common/PopUps/popDefinition.aspx?id=46339&version=healthprofessional&language=English&dictionary=Cancer.gov) [injections](/Common/PopUps/popDefinition.aspx?id=44678&version=healthprofessional&language=English&dictionary=Cancer.gov) of
amygdalin, with or without the enzyme beta-glucosidase. None of the [solid
tumors](/Common/PopUps/popDefinition.aspx?id=45301&version=healthprofessional&language=English&dictionary=Cancer.gov) or leukemias that were investigated responded to amygdalin at any [dose](/Common/PopUps/popDefinition.aspx?id=44664&version=healthprofessional&language=English&dictionary=Cancer.gov) that was tested.
No [statistically significant](/Common/PopUps/popDefinition.aspx?id=44167&version=healthprofessional&language=English&dictionary=Cancer.gov) increase in animal survival was observed in any
of the treatment groups. Similar results were obtained in another study using
human [breast cancer](/Common/PopUps/popDefinition.aspx?id=444971&version=healthprofessional&language=English&dictionary=Cancer.gov) and [colon cancer](/Common/PopUps/popDefinition.aspx?id=44237&version=healthprofessional&language=English&dictionary=Cancer.gov) [cells](/Common/PopUps/popDefinition.aspx?id=46476&version=healthprofessional&language=English&dictionary=Cancer.gov) implanted into mice.[[10](#cit/section_4.10)] Amygdalin at every dose level tested produced no [response](/Common/PopUps/popDefinition.aspx?id=44085&version=healthprofessional&language=English&dictionary=Cancer.gov) either as a single agent or in
combination with beta-glucosidase. It was discovered that animals
experienced more [side effects](/Common/PopUps/popDefinition.aspx?id=46580&version=healthprofessional&language=English&dictionary=Cancer.gov) when beta-glucosidase was given [concurrently](/Common/PopUps/popDefinition.aspx?id=44011&version=healthprofessional&language=English&dictionary=Cancer.gov) with amygdalin than when amygdalin was given alone.[[2](#cit/section_4.2),[3](#cit/section_4.3)]

Additional [cell culture](/Common/PopUps/popDefinition.aspx?id=556412&version=healthprofessional&language=English&dictionary=Cancer.gov) and animal studies involving more than a dozen
other tumor models have been published.[[1](#cit/section_4.1),[4](#cit/section_4.4),[6](#cit/section_4.6),[8](#cit/section_4.8),[9](#cit/section_4.9),[14](#cit/section_4.14),[15](#cit/section_4.15)] In
one study, preliminary findings by one of the principal [investigators](/Common/PopUps/popDefinition.aspx?id=44685&version=healthprofessional&language=English&dictionary=Cancer.gov) that
amygdalin inhibited the growth of [primary tumors](/Common/PopUps/popDefinition.aspx?id=45847&version=healthprofessional&language=English&dictionary=Cancer.gov) and the [incidence](/Common/PopUps/popDefinition.aspx?id=46145&version=healthprofessional&language=English&dictionary=Cancer.gov) of
lung [metastases](/Common/PopUps/popDefinition.aspx?id=46710&version=healthprofessional&language=English&dictionary=Cancer.gov) in mice bearing
spontaneous (not treatment-induced) [mammary](/Common/PopUps/popDefinition.aspx?id=44560&version=healthprofessional&language=English&dictionary=Cancer.gov) [adenocarcinomas](/Common/PopUps/popDefinition.aspx?id=46216&version=healthprofessional&language=English&dictionary=Cancer.gov) could not be
confirmed.[[4](#cit/section_4.4)] However, positive results were obtained in
another study.[[9](#cit/section_4.9)] A summary of study results is provided in [Table 1](/about-cancer/treatment/cam/hp/laetrile-pdq#_72) and [Table 2](/about-cancer/treatment/cam/hp/laetrile-pdq#_73) below.

Table 1. *[In Vitro](/Common/PopUps/popDefinition.aspx?id=45733&version=healthprofessional&language=English&dictionary=Cancer.gov)* Studiesa

| Reference | Cell Line | [Outcome](/Common/PopUps/popDefinition.aspx?id=467853&version=healthprofessional&language=English&dictionary=Cancer.gov) |
| --- | --- | --- |
|  |  |  |
| --- | --- | --- |
| mg = milligram(s); mL = milliliter(s). | | |
| aFor additional information and definition of terms, see text and the [NCI Dictionary of Cancer Terms](https://www.cancer.gov/publications/dictionaries/cancer-terms/ "https://www.cancer.gov/publications/dictionaries/cancer-terms/"). | | |
| [[15](#cit/section_4.15)] | Two human [acute myeloid leukemia](/Common/PopUps/popDefinition.aspx?id=46347&version=healthprofessional&language=English&dictionary=Cancer.gov) cell lines (KG-1 and HL-60) | A 50% inhibition of colony formation by both normal and leukemic cells was observed at an amygdalin [concentration](/Common/PopUps/popDefinition.aspx?id=683342&version=healthprofessional&language=English&dictionary=Cancer.gov) of 3.5 [mg](/Common/PopUps/popDefinition.aspx?id=44213&version=healthprofessional&language=English&dictionary=Cancer.gov)/[mL](/Common/PopUps/popDefinition.aspx?id=44214&version=healthprofessional&language=English&dictionary=Cancer.gov) using both [drug](/Common/PopUps/popDefinition.aspx?id=348921&version=healthprofessional&language=English&dictionary=Cancer.gov) sources; the colony-forming cells from the leukemic cell lines and normal marrow were found to be relatively resistant to amygdalin and its metabolites *in vitro*; there was no selective kill of clonogenic cells from the human leukemia cell lines as compared to normal [bone marrow](/Common/PopUps/popDefinition.aspx?id=45622&version=healthprofessional&language=English&dictionary=Cancer.gov) |
| [[16](#cit/section_4.16)] | SNU-C4 human colon cancer cells | Modest (10%–30%) cytotoxicity seen with amygdalin concentrations of 0.5–5.0 mg/mL |
| [[17](#cit/section_4.17)] | Human [prostate cancer](/Common/PopUps/popDefinition.aspx?id=445079&version=healthprofessional&language=English&dictionary=Cancer.gov) cell lines (DU145 and LNCaP) | [Dose-dependent](/Common/PopUps/popDefinition.aspx?id=44110&version=healthprofessional&language=English&dictionary=Cancer.gov) cytotoxicity in DU145 with amygdalin concentrations of 0.01–10 mg/mL and in LNCaP cells at concentrations of 0.1–10 mg/mL |
| [[18](#cit/section_4.18)] | HepG2 human [hepatoma](/Common/PopUps/popDefinition.aspx?id=46661&version=healthprofessional&language=English&dictionary=Cancer.gov) cells | IC50 of amygdalin alone was 458.10 mg/mL and with beta-D-glucosidase was 3.2 mg/mL |
| [[19](#cit/section_4.19)] | HeLa human [cervical cancer](/Common/PopUps/popDefinition.aspx?id=444973&version=healthprofessional&language=English&dictionary=Cancer.gov) cells | Modest (10%–50%) cytotoxicity seen with amygdalin concentrations of 5–20 mg/mL |

Table 2. *[In Vivo](/Common/PopUps/popDefinition.aspx?id=46352&version=healthprofessional&language=English&dictionary=Cancer.gov)* Studiesa

| Reference | [Animal Model](/Common/PopUps/popDefinition.aspx?id=43996&version=healthprofessional&language=English&dictionary=Cancer.gov) | Outcome |
| --- | --- | --- |
|  |  |  |
| --- | --- | --- |
| DMBA = dimethylbenz-alpha-anthracene; kg = [kilogram](/Common/PopUps/popDefinition.aspx?id=44576&version=healthprofessional&language=English&dictionary=Cancer.gov)(s); mg = milligram(s). | | |
| aFor additional information and definition of terms, see text and the [NCI Dictionary of Cancer Terms](https://www.cancer.gov/publications/dictionaries/cancer-terms/ "https://www.cancer.gov/publications/dictionaries/cancer-terms/"). | | |
| [[2](#cit/section_4.2)] | Four transplantable rodent tumors (L1210 [lymphoid](/Common/PopUps/popDefinition.aspx?id=46298&version=healthprofessional&language=English&dictionary=Cancer.gov) leukemia, P388 [lymphocytic leukemia](/Common/PopUps/popDefinition.aspx?id=330173&version=healthprofessional&language=English&dictionary=Cancer.gov), B16 melanoma, and Walker 256 carcinosarcoma) | No [antitumor](/Common/PopUps/popDefinition.aspx?id=446109&version=healthprofessional&language=English&dictionary=Cancer.gov) activity of amygdalin alone (25–3,200 mg/kg); [potentiation](/Common/PopUps/popDefinition.aspx?id=330176&version=healthprofessional&language=English&dictionary=Cancer.gov) of [toxicity](/Common/PopUps/popDefinition.aspx?id=445093&version=healthprofessional&language=English&dictionary=Cancer.gov) of amygdalin when combined with beta glucosidase |
| [[3](#cit/section_4.3)] | Three transplantable rodent tumors (osteogenic sarcoma, Lewis lung carcinoma, and P388 leukemia) | No antitumor activity at 20% of lethal dose (LD20) |
| [[4](#cit/section_4.4)] | DMBA-induced rat mammary carcinoma and the following transplanted [experimental](/Common/PopUps/popDefinition.aspx?id=44758&version=healthprofessional&language=English&dictionary=Cancer.gov) tumors: sarcoma 180, [plasma cell](/Common/PopUps/popDefinition.aspx?id=46230&version=healthprofessional&language=English&dictionary=Cancer.gov) tumor LPC-1, leukemia L1210, Mecca [lymphosarcoma](/Common/PopUps/popDefinition.aspx?id=44115&version=healthprofessional&language=English&dictionary=Cancer.gov), Ridgway osteogenic sarcoma, sarcoma T241, mammary carcinoma E0771, Taper [liver](/Common/PopUps/popDefinition.aspx?id=46312&version=healthprofessional&language=English&dictionary=Cancer.gov) tumor, Ehrlich carcinoma (solid and [ascites](/Common/PopUps/popDefinition.aspx?id=45601&version=healthprofessional&language=English&dictionary=Cancer.gov)), and Walker carcinosarcoma 256 | Not effective at treating, preventing, or delaying development of tumors |
| [[6](#cit/section_4.6)] | B16 melanoma and BW5147 AKR leukemia | Ineffective |
| [[9](#cit/section_4.9)] | Murine mammary adenocarcinoma | No effect of amygdalin alone. Enhanced antitumor activity of combination of [oral](/Common/PopUps/popDefinition.aspx?id=44068&version=healthprofessional&language=English&dictionary=Cancer.gov) [vitamin A](/Common/PopUps/popDefinition.aspx?id=45248&version=healthprofessional&language=English&dictionary=Cancer.gov), amygdalin given intramuscularly, and enzymes injected into and around the tumor |
| [[10](#cit/section_4.10)] | Human [breast](/Common/PopUps/popDefinition.aspx?id=304766&version=healthprofessional&language=English&dictionary=Cancer.gov) and [colon](/Common/PopUps/popDefinition.aspx?id=46462&version=healthprofessional&language=English&dictionary=Cancer.gov) [xenografts](/Common/PopUps/popDefinition.aspx?id=44095&version=healthprofessional&language=English&dictionary=Cancer.gov) | Inactive |
| [[19](#cit/section_4.19)] | HeLa human [cervical cancer](/Common/PopUps/popDefinition.aspx?id=444973&version=healthprofessional&language=English&dictionary=Cancer.gov) cell xenografts | Modest tumor growth inhibition in mice receiving 300 mg/kg intraperitoneally daily for 14 days |

The toxicity of laetrile appears to be dependent on the route of
administration. Oral administration is associated with much greater toxicity
than [intravenous](/Common/PopUps/popDefinition.aspx?id=46682&version=healthprofessional&language=English&dictionary=Cancer.gov), intraperitoneal, or intramuscular injection.[[1](#cit/section_4.1),[5](#cit/section_4.5),[7](#cit/section_4.7),[8](#cit/section_4.8),[12](#cit/section_4.12),[20](#cit/section_4.20)-[22](#cit/section_4.22)] As noted in the [History](/about-cancer/treatment/cam/hp/laetrile-pdq#_10) section, most
mammalian cells contain only trace amounts of the enzyme beta-glucosidase;[[23](#cit/section_4.23)]
however, this enzyme is present in [gastrointestinal tract](/Common/PopUps/popDefinition.aspx?id=46189&version=healthprofessional&language=English&dictionary=Cancer.gov)
[bacteria](/Common/PopUps/popDefinition.aspx?id=44123&version=healthprofessional&language=English&dictionary=Cancer.gov) and in many food plants.[[5](#cit/section_4.5),[7](#cit/section_4.7),[13](#cit/section_4.13),[24](#cit/section_4.24)-[26](#cit/section_4.26)]

Two studies
have examined the role of intestinal bacteria in the breakdown of
orally administered amygdalin.[[7](#cit/section_4.7),[27](#cit/section_4.27)] In one study, rats bred and raised
under [germ-free](/Common/PopUps/popDefinition.aspx?id=44032&version=healthprofessional&language=English&dictionary=Cancer.gov) conditions and rats
bred and raised under normal conditions were given oral amygdalin. The
germ-free rats exhibited no side effects from the compound, and their blood
concentrations of cyanide were indistinguishable from those of untreated rats.
Many of the rats with normal quantities of intestinal bacteria
showed signs of cyanide poisoning (e.g., lethargy and convulsions), and they
had high levels of cyanide in their blood. In the second study, rats were
either treated or not treated with the [antibiotic](/Common/PopUps/popDefinition.aspx?id=45967&version=healthprofessional&language=English&dictionary=Cancer.gov) neomycin before being given
oral amygdalin.[[5](#cit/section_4.5)] In this study, [urinary](/Common/PopUps/popDefinition.aspx?id=44093&version=healthprofessional&language=English&dictionary=Cancer.gov) excretion of detoxified cyanide
(i.e., thiocyanate) was measured. The amount of urinary thiocyanate was
40 times higher in rats that had not been given the antibiotic, indicating
that more amygdalin had been broken down in animals with normal amounts of
intestinal bacteria. In humans, as in rats, substantial breakdown of
amygdalin occurs in the [intestines](/Common/PopUps/popDefinition.aspx?id=46335&version=healthprofessional&language=English&dictionary=Cancer.gov);
however, little breakdown of amygdalin occurs in humans, with most of the intact compound eventually
excreted in urine.[[25](#cit/section_4.25),[28](#cit/section_4.28)]

###### References

1. Gostomski FE: The effects of amygdalin on the Krebs-2 carcinoma and adult and fetal DUB(ICR) mice. [Abstract] Diss Abstr Int B 39 (5): 2075-B, 1978.
2. Wodinsky I, Swiniarski JK: Antitumor activity of amygdalin MF (NSC-15780) as a single agent and with beta-glucosidase (NSC-128056) on a spectrum of transplantable rodent tumors. Cancer Chemother Rep 59 (5): 939-50, 1975 Sep-Oct. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1203898&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1203898&dopt=Abstract")
3. Laster WR, Schabel FM: Experimental studies of the antitumor activity of amygdalin MF (NSC-15780) alone and in combination with beta-glucosidase (NSC-128056). Cancer Chemother Rep 59 (5): 951-65, 1975 Sep-Oct. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1060511&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1060511&dopt=Abstract")
4. Stock CC, Tarnowski GS, Schmid FA, et al.: Antitumor tests of amygdalin in transplantable animal tumor systems. J Surg Oncol 10 (2): 81-8, 1978. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=642516&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=642516&dopt=Abstract")
5. Newton GW, Schmidt ES, Lewis JP, et al.: Amygdalin toxicity studies in rats predict chronic cyanide poisoning in humans. West J Med 134 (2): 97-103, 1981. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7222669&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7222669&dopt=Abstract")
6. Hill GJ, Shine TE, Hill HZ, et al.: Failure of amygdalin to arrest B16 melanoma and BW5147 AKR leukemia. Cancer Res 36 (6): 2102-7, 1976. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1268862&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1268862&dopt=Abstract")
7. Carter JH, McLafferty MA, Goldman P: Role of the gastrointestinal microflora in amygdalin (laetrile)-induced cyanide toxicity. Biochem Pharmacol 29 (3): 301-4, 1980. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7362642&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7362642&dopt=Abstract")
8. Khandekar JD, Edelman H: Studies of amygdalin (laetrile) toxicity in rodents. JAMA 242 (2): 169-71, 1979. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=448892&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=448892&dopt=Abstract")
9. Manner HW, DiSanti SJ, Maggio MI, et al.: Amygdalin, vitamin A and enzyme induced regression of murine mammary adenocarcinomas. J Manipulative Physiol Ther 1 (4): 246-8, 1978.
10. Ovejera AA, Houchens DP, Barker AD, et al.: Inactivity of DL-amygdalin against human breast and colon tumor xenografts in athymic (nude) mice. Cancer Treat Rep 62 (4): 576-8, 1978. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=418876&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=418876&dopt=Abstract")
11. Lewis JP: Laetrile. West J Med 127 (1): 55-62, 1977. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=327697&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=327697&dopt=Abstract")
12. Schmidt ES, Newton GW, Sanders SM, et al.: Laetrile toxicity studies in dogs. JAMA 239 (10): 943-7, 1978. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=203726&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=203726&dopt=Abstract")
13. Dorr RT, Paxinos J: The current status of laetrile. Ann Intern Med 89 (3): 389-97, 1978. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=356691&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=356691&dopt=Abstract")
14. Levi L, French WN, Bickis IJ, et al.: Laetrile: a study of its physicochemical and biochemical properties. Can Med Assoc J 92 (20): 1057-61, 1965.
15. Koeffler HP, Lowe L, Golde DW: Amygdalin (Laetrile): effect on clonogenic cells from human myeloid leukemia cell lines and normal human marrow. Cancer Treat Rep 64 (1): 105-9, 1980. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=6929726&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=6929726&dopt=Abstract")
16. Park HJ, Yoon SH, Han LS, et al.: Amygdalin inhibits genes related to cell cycle in SNU-C4 human colon cancer cells. World J Gastroenterol 11 (33): 5156-61, 2005. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16127745&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16127745&dopt=Abstract")
17. Chang HK, Shin MS, Yang HY, et al.: Amygdalin induces apoptosis through regulation of Bax and Bcl-2 expressions in human DU145 and LNCaP prostate cancer cells. Biol Pharm Bull 29 (8): 1597-602, 2006. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16880611&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16880611&dopt=Abstract")
18. Zhou C, Qian L, Ma H, et al.: Enhancement of amygdalin activated with β-D-glucosidase on HepG2 cells proliferation and apoptosis. Carbohydr Polym 90 (1): 516-23, 2012. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=24751072&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=24751072&dopt=Abstract")
19. Chen Y, Ma J, Wang F, et al.: Amygdalin induces apoptosis in human cervical cancer cell line HeLa cells. Immunopharmacol Immunotoxicol 35 (1): 43-51, 2013. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=23137229&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=23137229&dopt=Abstract")
20. Moertel CG, Ames MM, Kovach JS, et al.: A pharmacologic and toxicological study of amygdalin. JAMA 245 (6): 591-4, 1981. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7005480&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7005480&dopt=Abstract")
21. Newmark J, Brady RO, Grimley PM, et al.: Amygdalin (Laetrile) and prunasin beta-glucosidases: distribution in germ-free rat and in human tumor tissue. Proc Natl Acad Sci U S A 78 (10): 6513-6, 1981. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=6796962&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=6796962&dopt=Abstract")
22. Navarro MD: Five years experience with laetrile therapy in advanced cancer. Acta Unio Int Contr Cancrum 15(suppl 1): 209-21, 1959.
23. Conchie J, Findlay J, Levvy GA: Mammalian glycosidases: distribution in the body. Biochem J 71 (2): 318-25, 1959.
24. Herbert V: Laetrile: the cult of cyanide. Promoting poison for profit. Am J Clin Nutr 32 (5): 1121-58, 1979. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=219680&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=219680&dopt=Abstract")
25. Ames MM, Moyer TP, Kovach JS, et al.: Pharmacology of amygdalin (laetrile) in cancer patients. Cancer Chemother Pharmacol 6 (1): 51-7, 1981. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7273266&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7273266&dopt=Abstract")
26. Unproven methods of cancer management. Laetrile. CA Cancer J Clin 22 (4): 245-50, 1972 Jul-Aug. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=4625050&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=4625050&dopt=Abstract")
27. Shils ME, Hermann MG: Unproved dietary claims in the treatment of patients with cancer. Bull N Y Acad Med 58 (3): 323-40, 1982. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7052177&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7052177&dopt=Abstract")
28. Ames MM, Kovach JS, Flora KP: Initial pharmacologic studies of amygdalin (laetrile) in man. Res Commun Chem Pathol Pharmacol 22 (1): 175-85, 1978. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=725316&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=725316&dopt=Abstract")

## Human/Clinical Studies

[Laetrile](/Common/PopUps/popDefinition.aspx?id=444998&version=healthprofessional&language=English&dictionary=Cancer.gov) has been used as an anticancer treatment in humans
worldwide.[[1](#cit/section_5.1)] Although many [anecdotal reports](/Common/PopUps/popDefinition.aspx?id=43995&version=healthprofessional&language=English&dictionary=Cancer.gov) and [case reports](/Common/PopUps/popDefinition.aspx?id=44007&version=healthprofessional&language=English&dictionary=Cancer.gov) are available, findings
from only two [clinical trials](/Common/PopUps/popDefinition.aspx?id=45961&version=healthprofessional&language=English&dictionary=Cancer.gov) [[2](#cit/section_5.2),[3](#cit/section_5.3)] have been published. No [controlled clinical trial](/Common/PopUps/popDefinition.aspx?id=44014&version=healthprofessional&language=English&dictionary=Cancer.gov) of laetrile has ever been conducted.

Case reports and reports of [case series](/Common/PopUps/popDefinition.aspx?id=44006&version=healthprofessional&language=English&dictionary=Cancer.gov) have provided little
evidence to support laetrile as an anticancer
treatment.[[1](#cit/section_5.1),[4](#cit/section_5.4)-[8](#cit/section_5.8)] The absence of a uniform
documentation of [cancer](/Common/PopUps/popDefinition.aspx?id=45333&version=healthprofessional&language=English&dictionary=Cancer.gov) [diagnosis](/Common/PopUps/popDefinition.aspx?id=46450&version=healthprofessional&language=English&dictionary=Cancer.gov), the
use of [conventional therapies](/Common/PopUps/popDefinition.aspx?id=44198&version=healthprofessional&language=English&dictionary=Cancer.gov) in combination with laetrile, and variations in
the [dose](/Common/PopUps/popDefinition.aspx?id=44664&version=healthprofessional&language=English&dictionary=Cancer.gov) and duration of laetrile [therapy](/Common/PopUps/popDefinition.aspx?id=44737&version=healthprofessional&language=English&dictionary=Cancer.gov) complicate evaluation of the data.
In a case series published in 1962,[[6](#cit/section_5.6)] findings from ten patients with
various types of [metastatic](/Common/PopUps/popDefinition.aspx?id=44058&version=healthprofessional&language=English&dictionary=Cancer.gov) cancer
were reported. These patients had been treated with a wide range of doses of
[intravenous](/Common/PopUps/popDefinition.aspx?id=46682&version=healthprofessional&language=English&dictionary=Cancer.gov) (IV) Laetrile (total dose range, 9–133 [g](/Common/PopUps/popDefinition.aspx?id=373014&version=healthprofessional&language=English&dictionary=Cancer.gov)). Pain relief (reduction or elimination) was the primary benefit reported. Some
[objective responses](/Common/PopUps/popDefinition.aspx?id=44067&version=healthprofessional&language=English&dictionary=Cancer.gov), such as decreased [adenopathy](/Common/PopUps/popDefinition.aspx?id=43990&version=healthprofessional&language=English&dictionary=Cancer.gov) and decreased tumor size,
were noted. Information on prior or [concurrent therapy](/Common/PopUps/popDefinition.aspx?id=44011&version=healthprofessional&language=English&dictionary=Cancer.gov) was provided;
however, patients were not followed up long-term to determine whether the
benefits continued after treatment was stopped. Another case series that was
published in 1953 included 44 cancer patients and found no evidence of
objective response that could be attributed to laetrile.[[9](#cit/section_5.9)] Most patients
with reported cancer [regression](/Common/PopUps/popDefinition.aspx?id=46039&version=healthprofessional&language=English&dictionary=Cancer.gov) in
this series received recent or concurrent [radiation therapy](/Common/PopUps/popDefinition.aspx?id=44971&version=healthprofessional&language=English&dictionary=Cancer.gov) or [chemotherapy](/Common/PopUps/popDefinition.aspx?id=45214&version=healthprofessional&language=English&dictionary=Cancer.gov). Thus, it is impossible
to determine which treatment produced the positive results.

[Benzaldehyde](/Common/PopUps/popDefinition.aspx?id=44000&version=healthprofessional&language=English&dictionary=Cancer.gov), which is one of laetrile’s breakdown products, has also been
tested for anticancer activity in humans. Two [clinical series](/Common/PopUps/popDefinition.aspx?id=44010&version=healthprofessional&language=English&dictionary=Cancer.gov) reported a number
of responses to benzaldehyde in patients with advanced cancer for whom
[standard therapy](/Common/PopUps/popDefinition.aspx?id=44930&version=healthprofessional&language=English&dictionary=Cancer.gov) had failed.[[10](#cit/section_5.10),[11](#cit/section_5.11)] In one series, 19 [complete responses](/Common/PopUps/popDefinition.aspx?id=45652&version=healthprofessional&language=English&dictionary=Cancer.gov) and ten [partial responses](/Common/PopUps/popDefinition.aspx?id=45819&version=healthprofessional&language=English&dictionary=Cancer.gov) were reported
among 57 patients who had received either [oral](/Common/PopUps/popDefinition.aspx?id=44068&version=healthprofessional&language=English&dictionary=Cancer.gov) or [rectal](/Common/PopUps/popDefinition.aspx?id=44083&version=healthprofessional&language=English&dictionary=Cancer.gov) beta-cyclodextrin benzaldehyde;
however, precise response durations were specified for only two of the
patients.[[10](#cit/section_5.10)] Another series by the same [investigators](/Common/PopUps/popDefinition.aspx?id=44685&version=healthprofessional&language=English&dictionary=Cancer.gov) used
4,6-benzylidene-alpha-D-glucose, which is an IV formulation of
benzaldehyde.[[11](#cit/section_5.11)] In this series, seven complete responses and 29 partial
responses were reported among 65 patients, with response durations ranging
from 1.5 to 27 months. No [toxicity](/Common/PopUps/popDefinition.aspx?id=43986&version=healthprofessional&language=English&dictionary=Cancer.gov) was associated with either preparation of
benzaldehyde, and it was reported that the responses persisted as long as
treatment was continued. Almost all of the patients in these two series had
been treated previously with chemotherapy or radiation therapy, but the
elapsed time before the initiation of benzaldehyde treatment was not
disclosed.

In 1978, the [National Cancer Institute](/Common/PopUps/popDefinition.aspx?id=44266&version=healthprofessional&language=English&dictionary=Cancer.gov) (NCI) requested case reports from practitioners who believed
that their patients had benefitted from laetrile treatment.[[12](#cit/section_5.12)] Ninety-three cases
were submitted, and 67 were considered evaluable for response. An expert
panel concluded that two of the 67 patients had complete responses and that
four of the others had partial responses while using laetrile.[[13](#cit/section_5.13)] On the basis of
these six responses, the NCI agreed to sponsor [phase I](/Common/PopUps/popDefinition.aspx?id=45830&version=healthprofessional&language=English&dictionary=Cancer.gov) and [phase II clinical trials](/Common/PopUps/popDefinition.aspx?id=45831&version=healthprofessional&language=English&dictionary=Cancer.gov).

The phase I study was designed to test the doses, routes of administration,
and the schedule of administration judged representative of those used by
laetrile practitioners.[[3](#cit/section_5.3)] The study involved six cancer patients. The
investigators found that IV and oral amygdalin showed minimal
toxicity under the conditions evaluated; however, two patients who ate raw
almonds while undergoing oral treatment developed symptoms of cyanide
poisoning.

The phase II study was conducted in 1982 and was designed to test the types
of cancer that might benefit from laetrile treatment.[[2](#cit/section_5.2)] Most
patients had [breast](/Common/PopUps/popDefinition.aspx?id=444971&version=healthprofessional&language=English&dictionary=Cancer.gov), [colon](/Common/PopUps/popDefinition.aspx?id=44237&version=healthprofessional&language=English&dictionary=Cancer.gov), or [lung cancer](/Common/PopUps/popDefinition.aspx?id=445043&version=healthprofessional&language=English&dictionary=Cancer.gov). To be eligible for the trial,
patients had to be in good general condition (not totally disabled or near
death), and they must not have received any other cancer [therapy](/Common/PopUps/popDefinition.aspx?id=44737&version=healthprofessional&language=English&dictionary=Cancer.gov) for at least
1 month before treatment with [amygdalin](/Common/PopUps/popDefinition.aspx?id=454511&version=healthprofessional&language=English&dictionary=Cancer.gov). Amygdalin, evaluated for potency
and purity by the NCI,[[14](#cit/section_5.14)] was administered by IV for 21 days,
followed by oral [maintenance therapy](/Common/PopUps/popDefinition.aspx?id=45768&version=healthprofessional&language=English&dictionary=Cancer.gov), utilizing doses and procedures similar
to those evaluated in the phase I study. [Vitamins](/Common/PopUps/popDefinition.aspx?id=44744&version=healthprofessional&language=English&dictionary=Cancer.gov) and [pancreatic enzymes](/Common/PopUps/popDefinition.aspx?id=46704&version=healthprofessional&language=English&dictionary=Cancer.gov) were
also administered as part of a [metabolic therapy](/Common/PopUps/popDefinition.aspx?id=44057&version=healthprofessional&language=English&dictionary=Cancer.gov) program that included dietary
changes to restrict the use of caffeine, sugar, meats, dairy products, eggs,
and alcohol. A small subset of patients received higher-dose amygdalin
therapy and higher doses of some vitamins as part of the trial.
Patients were followed up until there was definite evidence of cancer [progression](/Common/PopUps/popDefinition.aspx?id=44078&version=healthprofessional&language=English&dictionary=Cancer.gov), elevated blood cyanide
levels, or severe clinical deterioration. Among 175 [evaluable patients](/Common/PopUps/popDefinition.aspx?id=44029&version=healthprofessional&language=English&dictionary=Cancer.gov), only one patient met the criteria for response. This patient, who had [gastric](/Common/PopUps/popDefinition.aspx?id=46770&version=healthprofessional&language=English&dictionary=Cancer.gov) carcinoma with [cervical](/Common/PopUps/popDefinition.aspx?id=44102&version=healthprofessional&language=English&dictionary=Cancer.gov) [lymph node](/Common/PopUps/popDefinition.aspx?id=45762&version=healthprofessional&language=English&dictionary=Cancer.gov) metastasis,
experienced a partial response that was maintained for 10 weeks while on
amygdalin therapy. Fifty-four percent of the patients had measurable disease
progression at the end of the IV course of treatment, and all
of the patients had disease progression 7 months after completing IV therapy.
Seven percent of the patients reported an improvement in performance status
(ability to work or to perform routine daily activities) at some time during
therapy, and 20 percent claimed [symptomatic](/Common/PopUps/popDefinition.aspx?id=44090&version=healthprofessional&language=English&dictionary=Cancer.gov) relief. In most patients,
these benefits did not persist. Blood cyanide levels were not elevated after
IV amygdalin treatment; however, they were elevated after oral
therapy.[[2](#cit/section_5.2)]

Variations in commercial preparations of laetrile from Mexico, the primary
supplier, have been documented.[[14](#cit/section_5.14),[15](#cit/section_5.15)] Incorrect product labels have been
found, and samples contaminated with [bacteria](/Common/PopUps/popDefinition.aspx?id=44123&version=healthprofessional&language=English&dictionary=Cancer.gov) and other substances have been
identified.[[14](#cit/section_5.14),[15](#cit/section_5.15)] When a comparison was made of products manufactured in the
United States and Canada, differences in chemical composition were noted, and
neither product was effective in killing cultured human cancer cells.[[16](#cit/section_5.16)]

Table 3. Clinical Studies of Laetrile/Amygdalina

| Reference | Trial Design | Condition or Cancer Type | Treatment Groups (Enrolled; Treated; [Placebo](/Common/PopUps/popDefinition.aspx?id=46688&version=healthprofessional&language=English&dictionary=Cancer.gov) or No Treatment Control)b | Results | Concurrent Therapy Used | Level of Evidencec |
| --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| N/A = not applicable. | | | | | | |
| aFor additional information and definition of terms, see text and the [NCI Dictionary of Cancer Terms](https://www.cancer.gov/publications/dictionaries/cancer-terms/ "https://www.cancer.gov/publications/dictionaries/cancer-terms/"). | | | | | | |
| bNumber of patients treated plus number of patient controls may not equal number of patients enrolled; number of patients enrolled equals number of patients initially recruited/considered by the researchers who conducted a study; number of patients treated equals number of enrolled patients who were given the treatment being studied AND for whom results were reported. | | | | | | |
| cStrongest evidence reported that the treatment under study has activity or otherwise improves the well-being of cancer patients. For information about [levels of evidence](/Common/PopUps/popDefinition.aspx?id=446533&version=healthprofessional&language=English&dictionary=Cancer.gov) analysis and scores, see [Levels of Evidence for Human Studies of Integrative, Alternative, and Complementary Therapies](/publications/pdq/levels-evidence/cam). | | | | | | |
| [[2](#cit/section_5.2)] | [Consecutive case series](/Common/PopUps/popDefinition.aspx?id=285747&version=healthprofessional&language=English&dictionary=Cancer.gov) | Various cancers | 179; 178; N/A | No benefit reported | Metabolic therapy program of [diet](/Common/PopUps/popDefinition.aspx?id=44660&version=healthprofessional&language=English&dictionary=Cancer.gov), vitamins, and [enzymes](/Common/PopUps/popDefinition.aspx?id=46081&version=healthprofessional&language=English&dictionary=Cancer.gov) | 3iiDiii |
| [[13](#cit/section_5.13)] | [Nonconsecutive case series](/Common/PopUps/popDefinition.aspx?id=44575&version=healthprofessional&language=English&dictionary=Cancer.gov) | Various diseases | 68; 68; 24 | Two patients had complete response; four patients had partial response | Chemotherapy | 3iiiDiii |
| [[3](#cit/section_5.3)] | Nonconsecutive case series | Advanced cancer | 6; 6; N/A | No benefit reported | Vitamins, enzymes | 3iiiDiii |
| [[6](#cit/section_5.6)] | Best case series | Various advanced cancers | 9; 9; N/A | Pain relief | Unknown | 4 |
| [[7](#cit/section_5.7)] | Best case series | Various cancers | 10; 10; N/A | Pain relief | [Narcotics](/Common/PopUps/popDefinition.aspx?id=44691&version=healthprofessional&language=English&dictionary=Cancer.gov) given to seven patients, but discontinued in five patients | 4 |
| [[9](#cit/section_5.9)] | Best case series | Various cancers | N/A; 44; N/A | No benefit reported | Unknown | 4 |

###### References

1. Lewis JP: Laetrile. West J Med 127 (1): 55-62, 1977. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=327697&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=327697&dopt=Abstract")
2. Moertel CG, Fleming TR, Rubin J, et al.: A clinical trial of amygdalin (Laetrile) in the treatment of human cancer. N Engl J Med 306 (4): 201-6, 1982. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7033783&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7033783&dopt=Abstract")
3. Moertel CG, Ames MM, Kovach JS, et al.: A pharmacologic and toxicological study of amygdalin. JAMA 245 (6): 591-4, 1981. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7005480&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7005480&dopt=Abstract")
4. Navarro MD: The Philippine experience in the early detection and chemotherapy of cancer. St Tomas J Med 25 (3): 125-33, 1970.
5. Ross WE: Unconventional cancer therapy. Compr Ther 11 (9): 37-43, 1985. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=4042595&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=4042595&dopt=Abstract")
6. Navarro MD: Five years experience with laetrile therapy in advanced cancer. Acta Unio Int Contr Cancrum 15(suppl 1): 209-21, 1959.
7. Morrone JA: Chemotherapy of inoperable cancer: preliminary report of 10 cases treated with laetrile. Exp Med Surg 20: 299-308, 1962.
8. Brown WE, Wood CD, Smith AN: Sodium cyanide as a cancer chemotherapeutic agent: laboratory and clinical studies. Am J Obstet Gynecol 80 (5): 907-18, 1960.
9. Treatment of cancer with laetriles; a report by the Cancer Commission of the California Medical Association. Calif Med 78 (4): 320-6, 1953. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=13042670&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=13042670&dopt=Abstract")
10. Kochi M, Takeuchi S, Mizutani T, et al.: Antitumor activity of benzaldehyde. Cancer Treat Rep 64 (1): 21-3, 1980. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=6929727&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=6929727&dopt=Abstract")
11. Kochi M, Isono N, Niwayama M, et al.: Antitumor activity of a benzaldehyde derivative. Cancer Treat Rep 69 (5): 533-7, 1985. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=4005876&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=4005876&dopt=Abstract")
12. Newell GR, Ellison NM: Ethics and designs: laetrile trials as an example. Cancer Treat Rep 64 (2-3): 363-5, 1980 Feb-Mar. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=6996807&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=6996807&dopt=Abstract")
13. Ellison NM, Byar DP, Newell GR: Special report on Laetrile: the NCI Laetrile Review. Results of the National Cancer Institute's retrospective Laetrile analysis. N Engl J Med 299 (10): 549-52, 1978. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=683212&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=683212&dopt=Abstract")
14. Davignon JP, Trissel LA, Kleinman LM: Pharmaceutical assessment of amygdalin (Laetrile) products. Cancer Treat Rep 62 (1): 99-104, 1978. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=627001&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=627001&dopt=Abstract")
15. Davignon JP: Contaminated laetrile: a health hazard. N Engl J Med 297 (24): 1355-6, 1977. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=917101&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=917101&dopt=Abstract")
16. Levi L, French WN, Bickis IJ, et al.: Laetrile: a study of its physicochemical and biochemical properties. Can Med Assoc J 92 (20): 1057-61, 1965.

## Adverse Effects

The [side effects](/Common/PopUps/popDefinition.aspx?id=46580&version=healthprofessional&language=English&dictionary=Cancer.gov) associated with [laetrile](/Common/PopUps/popDefinition.aspx?id=444998&version=healthprofessional&language=English&dictionary=Cancer.gov) treatment mirror the symptoms of
cyanide poisoning. Cyanide is a [neurotoxin](/Common/PopUps/popDefinition.aspx?id=44065&version=healthprofessional&language=English&dictionary=Cancer.gov) that can cause the following side effects:

- [Nausea](/Common/PopUps/popDefinition.aspx?id=390302&version=healthprofessional&language=English&dictionary=Cancer.gov) and
[vomiting](/Common/PopUps/popDefinition.aspx?id=390324&version=healthprofessional&language=English&dictionary=Cancer.gov).[[1](#cit/section_6.1)]
- Headache.[[1](#cit/section_6.1)]
- Dizziness.[[2](#cit/section_6.2),[3](#cit/section_6.3)]
- [Cyanosis](/Common/PopUps/popDefinition.aspx?id=44019&version=healthprofessional&language=English&dictionary=Cancer.gov).
- [Liver](/Common/PopUps/popDefinition.aspx?id=46312&version=healthprofessional&language=English&dictionary=Cancer.gov) damage.[[4](#cit/section_6.4),[5](#cit/section_6.5)]
- [Hypotension](/Common/PopUps/popDefinition.aspx?id=44039&version=healthprofessional&language=English&dictionary=Cancer.gov).[[1](#cit/section_6.1),[6](#cit/section_6.6),[7](#cit/section_6.7)]
- [Ptosis](/Common/PopUps/popDefinition.aspx?id=44081&version=healthprofessional&language=English&dictionary=Cancer.gov).[[8](#cit/section_6.8),[9](#cit/section_6.9)]
- [Ataxic](/Common/PopUps/popDefinition.aspx?id=43999&version=healthprofessional&language=English&dictionary=Cancer.gov) [neuropathies](/Common/PopUps/popDefinition.aspx?id=46041&version=healthprofessional&language=English&dictionary=Cancer.gov).[[10](#cit/section_6.10)]
- Fever.[[7](#cit/section_6.7),[8](#cit/section_6.8)]
- Mental confusion.[[6](#cit/section_6.6),[11](#cit/section_6.11)-[13](#cit/section_6.13)]
- Coma.[[6](#cit/section_6.6),[11](#cit/section_6.11)-[13](#cit/section_6.13)]
- Death.[[6](#cit/section_6.6),[11](#cit/section_6.11)-[13](#cit/section_6.13)]

[Oral](/Common/PopUps/popDefinition.aspx?id=44068&version=healthprofessional&language=English&dictionary=Cancer.gov) laetrile causes more severe side effects
than [injected](/Common/PopUps/popDefinition.aspx?id=44678&version=healthprofessional&language=English&dictionary=Cancer.gov) laetrile. These side effects can be potentiated by
the concurrent administration of raw almonds or crushed fruit pits, and by eating
fruits or vegetables that contain beta-glucosidase (e.g., celery, peaches,
bean sprouts, carrots),[[3](#cit/section_6.3),[5](#cit/section_6.5),[14](#cit/section_6.14)-[16](#cit/section_6.16)] or by taking high [doses](/Common/PopUps/popDefinition.aspx?id=44664&version=healthprofessional&language=English&dictionary=Cancer.gov) of
[vitamin](/Common/PopUps/popDefinition.aspx?id=44744&version=healthprofessional&language=English&dictionary=Cancer.gov) C orally.[[1](#cit/section_6.1),[5](#cit/section_6.5),[17](#cit/section_6.17),[18](#cit/section_6.18)]

###### References

1. Howard-Ruben J, Miller NJ: Unproven methods of cancer management. Part II: Current trends and implications for patient care. Oncol Nurs Forum 11 (1): 67-73, 1984 Jan-Feb. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=6318190&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=6318190&dopt=Abstract")
2. Moertel CG, Fleming TR, Rubin J, et al.: A clinical trial of amygdalin (Laetrile) in the treatment of human cancer. N Engl J Med 306 (4): 201-6, 1982. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7033783&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7033783&dopt=Abstract")
3. Chandler RF, Anderson LA, Phillipson JD: Laetrile in perspective. Can Pharm J 117 (11): 517-20, 1984.
4. Leor R, Michaeli J, Brezis M, et al.: Laetrile intoxication and hepatic necrosis: a possible association. South Med J 79 (2): 259-60, 1986. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=3003927&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=3003927&dopt=Abstract")
5. Lee M, Berger HW, Givre HL, et al.: Near fatal laetrile intoxication: complete recovery with supportive treatment. Mt Sinai J Med 49 (4): 305-7, 1982 Jul-Aug. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=6982404&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=6982404&dopt=Abstract")
6. Navarro MD: Five years experience with laetrile therapy in advanced cancer. Acta Unio Int Contr Cancrum 15(suppl 1): 209-21, 1959.
7. Dorr RT, Paxinos J: The current status of laetrile. Ann Intern Med 89 (3): 389-97, 1978. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=356691&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=356691&dopt=Abstract")
8. Smith FP, Butler TP, Cohan S, et al.: Laetrile toxicity: a report of two patients. Cancer Treat Rep 62 (1): 169-71, 1978. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=203395&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=203395&dopt=Abstract")
9. Vizel M, Oster MW: Ocular side effects of cancer chemotherapy. Cancer 49 (10): 1999-2002, 1982. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7074524&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7074524&dopt=Abstract")
10. Kalyanaraman UP, Kalyanaraman K, Cullinan SA, et al.: Neuromyopathy of cyanide intoxication due to "laetrile" (amygdalin). A clinicopathologic study. Cancer 51 (11): 2126-33, 1983. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=6301673&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=6301673&dopt=Abstract")
11. Ames MM, Moyer TP, Kovach JS, et al.: Pharmacology of amygdalin (laetrile) in cancer patients. Cancer Chemother Pharmacol 6 (1): 51-7, 1981. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7273266&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7273266&dopt=Abstract")
12. Moertel CG, Ames MM, Kovach JS, et al.: A pharmacologic and toxicological study of amygdalin. JAMA 245 (6): 591-4, 1981. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7005480&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7005480&dopt=Abstract")
13. O'Brien B, Quigg C, Leong T: Severe cyanide toxicity from 'vitamin supplements'. Eur J Emerg Med 12 (5): 257-8, 2005. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16175068&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16175068&dopt=Abstract")
14. Gostomski FE: The effects of amygdalin on the Krebs-2 carcinoma and adult and fetal DUB(ICR) mice. [Abstract] Diss Abstr Int B 39 (5): 2075-B, 1978.
15. Schmidt ES, Newton GW, Sanders SM, et al.: Laetrile toxicity studies in dogs. JAMA 239 (10): 943-7, 1978. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=203726&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=203726&dopt=Abstract")
16. Herbert V: Laetrile: the cult of cyanide. Promoting poison for profit. Am J Clin Nutr 32 (5): 1121-58, 1979. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=219680&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=219680&dopt=Abstract")
17. Calabrese EJ: Conjoint use of laetrile and megadoses of ascorbic acid in cancer treatment: possible side effects. Med Hypotheses 5 (9): 995-7, 1979. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=522711&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=522711&dopt=Abstract")
18. Bromley J, Hughes BG, Leong DC, et al.: Life-threatening interaction between complementary medicines: cyanide toxicity following ingestion of amygdalin and vitamin C. Ann Pharmacother 39 (9): 1566-9, 2005. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16014371&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16014371&dopt=Abstract")

## Summary of the Evidence for Laetrile/Amygdalin

To assist readers in evaluating the results of human studies of integrative, alternative, and complementary therapies for [cancer](/Common/PopUps/popDefinition.aspx?id=45333&version=healthprofessional&language=English&dictionary=Cancer.gov), the strength of the evidence (i.e., the [levels of
evidence](/Common/PopUps/popDefinition.aspx?id=446533&version=healthprofessional&language=English&dictionary=Cancer.gov)) associated with each type of treatment is provided whenever
possible. To qualify for a level of evidence analysis, a study must:

- Be published in a peer-reviewed scientific journal.
- Report on a [therapeutic](/Common/PopUps/popDefinition.aspx?id=43985&version=healthprofessional&language=English&dictionary=Cancer.gov) outcome or outcomes, such as [tumor](/Common/PopUps/popDefinition.aspx?id=46634&version=healthprofessional&language=English&dictionary=Cancer.gov) [response](/Common/PopUps/popDefinition.aspx?id=44085&version=healthprofessional&language=English&dictionary=Cancer.gov), improvement in survival, or measured improvement in [quality of life](/Common/PopUps/popDefinition.aspx?id=45417&version=healthprofessional&language=English&dictionary=Cancer.gov).
- Describe clinical findings in sufficient detail that a meaningful evaluation can be made.

Separate levels of evidence scores are assigned to qualifying human studies on the basis of statistical strength of the study design and scientific strength of the treatment outcomes (i.e., [endpoints](/Common/PopUps/popDefinition.aspx?id=346519&version=healthprofessional&language=English&dictionary=Cancer.gov)) measured. The resulting two scores are then combined to produce an overall score. For an explanation of the scores and additional information about levels of evidence analysis for cancer, see [Levels of Evidence for Human Studies of Integrative, Alternative, and Complementary Therapies](/publications/pdq/levels-evidence/cam).

## Latest Updates to This Summary (06/14/2022)

The [PDQ](/Common/PopUps/popDefinition.aspx?id=44271&version=healthprofessional&language=English&dictionary=Cancer.gov) [cancer](/Common/PopUps/popDefinition.aspx?id=45333&version=healthprofessional&language=English&dictionary=Cancer.gov) information summaries are reviewed regularly and updated as
new information becomes available. This section describes the latest
changes made to this summary as of the date above.

Editorial changes were made to this summary.

This summary is written and maintained by the [PDQ Integrative, Alternative, and Complementary Therapies Editorial Board](https://www.cancer.gov/publications/pdq/editorial-boards/cam "https://www.cancer.gov/publications/pdq/editorial-boards/cam"), which is
editorially independent of NCI. The summary reflects an independent review of
the literature and does not represent a policy statement of NCI or NIH. More
information about summary policies and the role of the PDQ Editorial Boards in
maintaining the PDQ summaries can be found on the [About This PDQ Summary](/about-cancer/treatment/cam/hp/laetrile-pdq#_AboutThis_1) and [PDQ® Cancer Information for Health Professionals](https://www.cancer.gov/publications/pdq "https://www.cancer.gov/publications/pdq") pages.

## About This PDQ Summary

### Purpose of This Summary

This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the use of laetrile/amygdalin in the treatment of people with cancer. It is intended as a resource to inform and assist clinicians in the care of their patients. It does not provide formal guidelines or recommendations for making health care decisions.

### Reviewers and Updates

This summary is reviewed regularly and updated as necessary by the [PDQ Integrative, Alternative, and Complementary Therapies Editorial Board](https://www.cancer.gov/publications/pdq/editorial-boards/cam "https://www.cancer.gov/publications/pdq/editorial-boards/cam"), which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).

Board members review recently published articles each month to determine whether an article should:

- be discussed at a meeting,
- be cited with text, or
- replace or update an existing article that is already cited.

Changes to the summaries are made through a consensus process in which Board members evaluate the strength of the evidence in the published articles and determine how the article should be included in the summary.

Any comments or questions about the summary content should be submitted to Cancer.gov through the NCI website's [Email Us](https://www.cancer.gov/contact/email-us "https://www.cancer.gov/contact/email-us"). Do not contact the individual Board Members with questions or comments about the summaries. Board members will not respond to individual inquiries.

### Levels of Evidence

Some of the reference citations in this summary are accompanied by a level-of-evidence designation. These designations are intended to help readers assess the strength of the evidence supporting the use of specific interventions or approaches. The PDQ Integrative, Alternative, and Complementary Therapies Editorial Board uses a [formal evidence ranking system](/publications/pdq/levels-evidence/cam) in developing its level-of-evidence designations.

### Permission to Use This Summary

PDQ is a registered trademark. Although the content of PDQ documents can be used freely as text, it cannot be identified as an NCI PDQ cancer information summary unless it is presented in its entirety and is regularly updated. However, an author would be permitted to write a sentence such as “NCI’s PDQ cancer information summary about breast cancer prevention states the risks succinctly: [include excerpt from the summary].”

The preferred citation for this PDQ summary is:

PDQ® Integrative, Alternative, and Complementary Therapies Editorial Board. PDQ Laetrile/Amygdalin. Bethesda, MD: National Cancer Institute. Updated <MM/DD/YYYY>. Available at: [https://www.cancer.gov/about-cancer/treatment/cam/hp/laetrile-pdq](https://www.cancer.gov/about-cancer/treatment/cam/hp/laetrile-pdq "https://www.cancer.gov/about-cancer/treatment/cam/hp/laetrile-pdq"). Accessed <MM/DD/YYYY>. [PMID: 26389425]

Images in this summary are used with permission of the author(s), artist, and/or publisher for use within the PDQ summaries only. Permission to use images outside the context of PDQ information must be obtained from the owner(s) and cannot be granted by the National Cancer Institute. Information about using the illustrations in this summary, along with many other cancer-related images, is available in [Visuals Online](https://visualsonline.cancer.gov/ "https://visualsonline.cancer.gov/"), a collection of over 2,000 scientific images.

### Disclaimer

The information in these summaries should not be used as a basis for insurance reimbursement determinations. More information on insurance coverage is available on Cancer.gov on the [Managing Cancer Care](https://www.cancer.gov/about-cancer/managing-care "https://www.cancer.gov/about-cancer/managing-care") page.

### Contact Us

More information about contacting us or receiving help with the Cancer.gov website can be found on our [Contact Us for Help](https://www.cancer.gov/contact "https://www.cancer.gov/contact") page. Questions can also be submitted to Cancer.gov through the website’s [Email Us](https://www.cancer.gov/contact/email-us "https://www.cancer.gov/contact/email-us").
